Perspective Therapeutics announced the completion of cohort 1 dosing in the Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET in patients with unresectable or metastatic somatostatin receptor type 2-expressing neuroendocrine tumors. This milestone follows the recent completion of the first dose escalation cohort for Perspective’s melanoma therapeutic (212Pb)VMT01. The Company currently has two active clinical trial sites for the trial and anticipates that two additional sites will become operational in December, coinciding with the launch of cohort 2. Overall, the Company remains on track to launch an additional 14 clinical trial sites throughout the U.S. including the Mayo Clinic, the University of Iowa and more.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CATX:
- Perspective Therapeutics initiated with a Buy at JonesResearch
- Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights
- Perspective announces first patient dosed in Phase 1/2a study of VMT-a-NET
- Perspective completes recruitment for first patient cohort in VMT01 trial
- Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma